Safety and Efficacy of Aspirin in Stroke Patients With Glucose-6-phosphate Dehydrogenase Deficiency (SAST)
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Aspirin was reported to induce hemolysis in patients with glucose-6-phosphate dehydrogenase
(G6PD) deficiency on some occasions, while still widely uesd for stroke prevention. The SAST
trial is designed to evaluate the safety and efficacy of aspirin in patients this enzyme
disorder.The primary purpose of the trial is to evaluate the hemolytic effects of a 3-month
regimen of aspirin 100mg/d versus a 3-month regimen of clopidogrel 75mg/d.